new name for OXB-101 (gene therapy)

[Kevin51]

"Oxford BioMedica, one of Britain’s oldest biotech companies, has concluded a $842m deal with Axovant Sciences of the US to commercialise its gene therapy for Parkinson’s disease.

Axovant Sciences will fund all clinical and manufacturing development costs for the product, which will be called AXO-Lenti-PD.

The deal will accelerate the clinical testing of Oxford BioMedica’s Parkinson’s disease gene therapy, which started about ten years ago."

Slow progress! Has to be an expensive therapy if it passes Phase III; early results sound hopeful

ncbi.nlm.nih.gov/pubmed/244...

[park_bear]

The stock market is all excited about this one - Axovant has doubled today. Long road ahead since this has not even passed phase I. Also this treatment requires an injection into the brain so it may have trouble competing against thiamine ; - )

[Kevin51 in reply to park_bear]

The article link reports good Phase I/II results but they were open label and I guess the numbers were too small

[park_bear in reply to Kevin51]

That was the previous version. They have a new and improved version so they have to redo phase I.